21 completed, 4 unknown, 3 not yet recruiting, 3 recruiting. 10 Phase 2, 7 Not applicable, 7 Phase 3, 5 Phase 1, 2 Phase 4.
Follow Onchocerciasis: new trials by email Literature Review of Onchocerciasis trials Research Report on Onchocerciasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations Modified Mass Administration of Medicines Strategy, Albendazole 400 mg, Praziquantel 40 mg/kg - Onchocerciasis (River Blindness), Schistosomiasis | Not applicable | Recruiting | Uwemedimo Friday Ekpo | 5760 | 2026-07-01 | 2026-07-16 |
| Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers A mobile app with AI functionality for diagnosing skin-related NTDs - Skin and Connective Tissue Diseases, Neglected Tropical Diseases | Not applicable | Not yet recruiting | Kenya Medical Research Institute | 2420 | 2026-05-01 | 2026-04-02 |
| Integrating Mental Health Into Neglected Tropical Disease Care in Ghana WHO Essential Care package for mental health and NTDs - Leprosy, Lymphatic Filariases | Not applicable | Not yet recruiting | Liverpool School of Tropical Medicine | 200 | 2025-11-01 | 2025-11-25 |
| Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases Moxidectin, Ivermectin - Onchocerciasis, Ascaris Lumbricoides Infection | Phase 4 | Recruiting | Kirby Institute | 52000 | 2025-08-04 | 2025-11-21 |
| 21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia Albendazole 400mg, Placebo - Loiasis With Positive Blood Microfilaremia, Loiasis | Phase 3 | Not yet recruiting | Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 100 | 2025-01-15 | 2024-09-26 |
| A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects Levamisole 3 days, Levamisole 5 days, Placebo - Loiasis | Phase 2 / Phase 3 | Unknown | Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 99 | 2024-06-21 | 2024-09-20 |
| A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants BAY 44-4400 - Soil-transmitted Helminth Infection, Onchocerciasis (River Blindness) | Phase 1 | Completed | Bayer | 14 | 2024-05-07 | 2024-09-27 |
| Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination Biological samples collection (blood drawing + feces) - Onchocerciasis, Loiasis | Not applicable | Completed | Bioaster | 1128 | 2024-04-15 | 2026-09-30 |
| Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis Ivermectin w/ Albendazole, Ivermectin + Diethylcarbamazine + Albendazole, Moxidectin + Albendazole - Onchocercal Subcutaneous Nodule, Onchocerciasis | Phase 2 | Active not recruiting | Washington University School of Medicine | 300 | 2024-04-05 | 2025-12-18 |
| Onchocerciasis-Associated Epilepsy, an Explorative Case-control Study nodulectomy - Onchocercal Subcutaneous Nodule, Epilepsy | Unknown | Universiteit Antwerpen | 40 | 2023-06-01 | 2023-05-22 | |
| Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa LTS-2 DEC patch, Skin snips - Onchocerciasis, Loiasis | Not applicable | Withdrawn | Center for Research on Filariasis and Other Tropical Diseases, Cameroon | 2022-09-01 | 2025-03-25 | |
| PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole Tablets Oxfendazole, Placebo - Filariasis | Phase 1 | Completed | Swiss Tropical & Public Health Institute | 30 | 2022-04-21 | 2022-12-20 |
| Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients Moxidectin 2 MG Oral Tablet, Ivermectin 3Mg Tab, Placebo oral tablet - Onchocerciasis, Ocular, Loiasis | Phase 2 | Completed | Center for Research on Filariasis and Other Tropical Diseases, Cameroon | 72 | 2022-04-07 | 2025-02-24 |
| Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug AWZ1066S, Placebo - Filariasis, Lymphatic, Onchocerciasis | Phase 1 | Terminated | Liverpool School of Tropical Medicine | 30 | 2021-12-10 | 2023-09-21 |
| Emodepside Phase II Trial for Treatment of Onchocerciasis emodepside, matching placebo of emodepside, ivermectin - Onchocerciasis | Phase 2 | Unknown | Drugs for Neglected Diseases | 578 | 2021-08-30 | 2024-03-05 |
| Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection ABBV-4083, Placebo for ABBV-4083, Albendazole - Onchocerciasis | Phase 2 | Terminated | AbbVie | 153 | 2021-05-22 | 2024-09-19 |
| Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis Moxidectin, Ivermectin - Onchocerciasis | Phase 3 | Active not recruiting | Medicines Development for Global Health | 323 | 2021-05-03 | 2025-12-23 |
| Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole Moxidectin, Ivermectin, Albendazole - Onchocerciasis | Phase 3 | Completed | Medicines Development for Global Health | 12979 | 2021-05-03 | 2026-03-03 |
| A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years Moxidectin - Onchocerciasis | Phase 1 | Completed | Medicines Development for Global Health | 36 | 2021-03-29 | 2025-09-05 |
| Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients LEV 1 mg/kg, LEV 1,5 mg/kg, LEV 2,5 mg/kg - Onchocerciasis, Ocular, Loiasis | Phase 2 | Completed | Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 255 | 2021-01-16 | 2021-09-20 |
Showing 20 of 37. Sign in to see all of them.
Onchocerciasis, Ocular (10) · Filariasis (8) · Elephantiasis, Filarial (7) · Neglected Diseases (7) · Loiasis (6) · Epilepsy (5) · Parasitic Diseases (4) · Helminthiasis (3) · Infections (3) · Buruli Ulcer (2) · Leprosy (2) · Mansonelliasis (2) · Nematode Infections (2) · Scabies (2)
Secernentea Infections (36) · Spirurida Infections (36) · Nematode Infections (35) · Helminthiasis (34) · Infections (34) · Parasitic Diseases (33) · Skin Diseases (33) · Skin Diseases, Infectious (33) · Skin Diseases, Parasitic (33) · Skin and Connective Tissue Diseases (33) · Filariasis (29) · Vector Borne Diseases (16) · Eye Diseases (10) · Eye Infections (10) · Eye Infections, Parasitic (10)
Ivermectin (14) · moxidectin (9) · Albendazole (8) · Bay 44-4400 (3) · Albumins (2) · Diethylcarbamazine (2) · Levamisole (2) · emodepside (2) · Azithromycin (1) · Blood Specimen Collection (1) · Defecation (1) · Intravital Microscopy (1) · Mass Drug Administration (1) · Mebendazole (1) · Mental Health (1)
Medicines Development for Global Health (5) · Washington University School of Medicine (5) · Programme National de Lutte contre l'Onchocercose, Republic of the Congo (3) · Universiteit Antwerpen (3) · Center for Research on Filariasis and Other Tropical Diseases, Cameroon (2) · Drugs for Neglected Diseases (2) · Liverpool School of Tropical Medicine (2) · University Hospitals Cleveland Medical Center (2) · AbbVie (1) · Bayer (1) · Bioaster (1) · Centers for Disease Control and Prevention (1) · Heidelberg University (1) · Kenya Medical Research Institute (1) · Kirby Institute (1)
Ghana (9) · Democratic Republic of the Congo (7) · Cameroon (3) · Liberia (3) · Tanzania (3) · Côte d’Ivoire (2) · Nigeria (2) · Republic of the Congo (2) · South Sudan (2) · United Kingdom (2) · Angola (1) · Ethiopia (1) · Germany (1) · Guatemala (1) · Kenya (1)
Gary Weil, MD (3) · Gary J Weil, MD (2) · Peter U Fischer, PhD (2) · Tony Ukety, MD, DO, MPH (2) · Aboulaye Miete, MD (1) · Benjamin Koudou, PhD (1) · Bruno Mmbando, PhD (1) · Christopher King, MD PhD (1) · Christopher King, MD, PhD (1) · Christopher L King, MD, PhD (1) · Daniel A Boakye, PhD (1)
PMID 24968000, PMID 28855148, PMID 29361335, PMID 31314757, PMID 31923177, PMID 32055862, PMID 32561912, PMID 32976514, PMID 34651190, PMID 35476631, PMID 37205721, PMID 37243712, PMID 37535695, PMID 38439783, PMID 38587077, PMID 38924387, PMID 38966851, PMID 40615414, PMID 40707999, PMID 41121745, PMID 41662151, PMID 41705834
2015 (1), 2023 (1)